Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis.

Publication ,  Journal Article
Awad, K; Mikhailidis, DP; Toth, PP; Jones, SR; Moriarty, P; Lip, GYH; Muntner, P; Catapano, AL; Pencina, MJ; Rosenson, RS; Rysz, J; Banach, M ...
Published in: Cardiovasc Drugs Ther
August 2017

PURPOSE: We conducted a meta-analysis of randomized controlled trials (RCTs) and quasi-RCTs to synthesize evidence about the efficacy and safety of alternate-day vs daily dosing of statins. METHODS: We searched selected databases through January 2, 2017 to identify relevant RCTs and quasi-RCTs. The primary outcome was change in low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and triglycerides (TG), while secondary outcomes included adverse events and adherence. RESULTS: Twelve RCTs and 1 quasi-RCT (n = 1023 patients) were included in the analysis. Pooled analysis revealed no statistically significant difference between alternate-day and daily regimens of atorvastatin and rosuvastatin in terms of change in LDL-C (mean difference [MD] 6.79 mg/dL, 95% confidence interval [CI] -1.59, 15.17, p = 0.11, and 10.51 mg/dL, 95%CI -0.23, 21.26, p = 0.06, respectively) and TG (p > 0.05). Daily regimens of atorvastatin and rosuvastatin were superior to alternate-day regimes in term of change in TC (MD 12.45 mg/L, 95%CI 8.14, 16.76, p < 0.00001, and 15.80 mg/dL, 95%CI 5.66, 25.95, p = 0.002, respectively). For all outcomes, there was no statistically significant difference between alternate-day and daily regimens for both fluvastatin and pravastatin (p > 0.05). Both regimens of statins were generally well tolerated with good adherence. CONCLUSIONS: Alternate-day dosing of individual statins (especially atorvastatin and rosuvastatin) is as efficacious as daily dosing on LDL-C and TG.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cardiovasc Drugs Ther

DOI

EISSN

1573-7241

Publication Date

August 2017

Volume

31

Issue

4

Start / End Page

419 / 431

Location

United States

Related Subject Headings

  • Triglycerides
  • Randomized Controlled Trials as Topic
  • Medication Adherence
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Drug Administration Schedule
  • Cholesterol, LDL
  • Cholesterol
  • Cardiovascular System & Hematology
  • 3214 Pharmacology and pharmaceutical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Awad, K., Mikhailidis, D. P., Toth, P. P., Jones, S. R., Moriarty, P., Lip, G. Y. H., … Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group, . (2017). Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther, 31(4), 419–431. https://doi.org/10.1007/s10557-017-6743-0
Awad, Kamal, Dimitri P. Mikhailidis, Peter P. Toth, Steven R. Jones, Patrick Moriarty, Gregory Y. H. Lip, Paul Muntner, et al. “Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis.Cardiovasc Drugs Ther 31, no. 4 (August 2017): 419–31. https://doi.org/10.1007/s10557-017-6743-0.
Awad K, Mikhailidis DP, Toth PP, Jones SR, Moriarty P, Lip GYH, et al. Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther. 2017 Aug;31(4):419–31.
Awad, Kamal, et al. “Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis.Cardiovasc Drugs Ther, vol. 31, no. 4, Aug. 2017, pp. 419–31. Pubmed, doi:10.1007/s10557-017-6743-0.
Awad K, Mikhailidis DP, Toth PP, Jones SR, Moriarty P, Lip GYH, Muntner P, Catapano AL, Pencina MJ, Rosenson RS, Rysz J, Banach M, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther. 2017 Aug;31(4):419–431.
Journal cover image

Published In

Cardiovasc Drugs Ther

DOI

EISSN

1573-7241

Publication Date

August 2017

Volume

31

Issue

4

Start / End Page

419 / 431

Location

United States

Related Subject Headings

  • Triglycerides
  • Randomized Controlled Trials as Topic
  • Medication Adherence
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Humans
  • Drug Administration Schedule
  • Cholesterol, LDL
  • Cholesterol
  • Cardiovascular System & Hematology
  • 3214 Pharmacology and pharmaceutical sciences